Testing two HER2 breast cancer medicines before surgery
Part of Cancer clinical trials.
This trial compares two anti-HER2 medicines given before surgery to shrink HER2-positive early breast cancer. It aims to see which treatment works better as “neoadjuvant” therapy to improve outcomes while keeping you safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 70 years old.
- Your breast cancer is HER2-positive invasive cancer (lab test shows HER2 IHC 3+ or IHC 2+ with a gene amplification test).
- Your cancer is early stage: T2 to T4d, or T1c if lymph nodes under your arm are positive (not spread to distant organs).
- Your doctor can measure at least one visible tumor spot on ultrasound, mammogram, or MRI in the last month.
- Your heart is strong enough for chemotherapy (left ventricle ejection fraction 55% or higher on heart ultrasound).
- You have adequate blood counts and organ function on recent blood tests, and your cancer has not been treated already with chemo, hormone therapy, targeted therapy, or radiation for this disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial compares nab-PH plus pyrrolitinib versus TCbHP as treatment given before breast surgery. It aims to see which option works better and is safe for people with HER2-positive invasive breast cancer.
This trial compares two different drug combinations given before surgery to shrink HER2-positive breast cancer tumors. The goal is to see which combination works better and has fewer side effects.
This trial tests a combination of two targeted drugs (SHR-A1811 and pertuzumab) given before surgery to shrink HER2-positive breast cancer. It aims to see if this approach improves outcomes for patients with early-stage but high-risk disease.
This trial tests a neoadjuvant (before surgery) treatment plan for people with early-stage HER2-positive breast cancer. The goal is to see if a personalized approach can improve outcomes.
This trial tests a combination of two drugs, trastuzumab deruxtecan (SHR-A1811) and pertuzumab, given before surgery to shrink HER2-positive breast cancer. It is for women with stage II or III breast cancer who have not yet had treatment and are in good overall health.
This trial tests two different combinations of chemotherapy and targeted therapy given before surgery for HER2-positive breast cancer. The goal is to see which combination works better at shrinking the tumor.
Hear when a new Breast Cancer,HER2-positive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.